ImmunoGen, Inc. (NASDAQ:IMGN) is reporting third quarter financial results on Friday 6th November 2020, before market open.
According to analysts surveyed by Thomson Reuters, IMGN is expected to report 3Q20 loss of $ 0.18 per share from revenue of $ 15.36 million.
For the full year, analysts anticipate top line of $ 66.96 million, while looking forward to loss of $ 0.67 per share bottom line.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 60.00 million ~ $ 65.00 million
Click Here For More Historical Outlooks Of ImmunoGen, Inc.
Previous Quarter Performance
ImmunoGen, Inc. communicated loss for the second quarter of $ 0.14 per share, from the revenue of $ 15.03 million. According to street consensus, IMGN was expected to report 2Q20 loss of $ 0.17 per share from revenue of $ 14.59 million. The bottom line results beat street analysts by $ 0.03 or 17.65 percent, at the same time, top line results outshined analysts by $ 0.44 million or 3.02 percent.
Stock Performance
Shares of ImmunoGen, Inc. traded low $ -0.01 or -0.17 percent on Thursday, reaching $ 6.05 with volume of 2.43 million shares. ImmunoGen, Inc. has traded high as $ 6.16 and has cracked $ 5.85 on the downward trend
According to the previous trading day, closing price of $ 6.05, representing a 210.77 % increase from the 52 week low of $ 1.95 and a 14.29 % decrease over the 52 week high of $ 7.07.
The company has a market capital of $ 1.13 billion and is part of the Healthcare sector and Biotechnology industry.
Recent Analyst recommendations
- On 6th October 2020, maintained by SVB Leerink at Market Perform rating, with $ 5.00 target price.
- On 2nd October 2020, upgraded by Guggenheim to Buy from Neutral rating.
Conference Call
ImmunoGen, Inc. will be hosting a conference call at 8:00 AM eastern time on 6th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.immunogen.com
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. Its product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha, which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; IMGN779 that is in Phase I clinical trial for the treatment of acute myeloid leukemia (AML); and IMGN632, a CD123-targeting ADC that is in Phase I clinical trial for treating AML and blastic plasmacytoid dendritic cell neoplasm. ImmunoGen, Inc.
